MktsMarkets

GRI Bio, Inc.
NASDAQ: GRIKey statistics
GRI News
Stories mentioning GRI from around the web — every one is an open thread, so give it a like or add your take.
Loading news…
Financial statements
As filed, straight from the 10-Q — up to 19 years of history, free, with every line item chartable.
| Line item | Q1 '26Mar 31 | Q4 '25Dec 31 | Q3 '25Sep 30 | Q2 '25Jun 30 | Q1 '25Mar 31 | Q4 '24Dec 31 | Q3 '24Sep 30 | Q2 '24Jun 30 |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | ||||||||
| Cost of Goods Sold | ||||||||
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | ||||||||
| Research & Development | 361.00 | 1,531 | 1,769 | 1,879 | 1,640 | 833.00 | 1,125 | 877.00 |
| Sales General & Admin | ||||||||
| Total Operating Expenses | 2,003 | 2,664 | 3,365 | 2,897 | 3,051 | 1,953 | 2,130 | 2,257 |
| Operating Income (Loss) | (2,003) | (2,664) | (3,365) | (2,897) | (3,051) | (1,953) | (2,130) | (2,257) |
| Interest Income | ||||||||
| Interest Expense | ||||||||
| Other Expense | 0.00 | |||||||
| Pretax Income | ||||||||
| Tax Provision | ||||||||
| Net Income (Loss) | (1,998) | (2,659) | (3,359) | (2,892) | (3,046) | (1,947) | (2,123) | (2,250) |
| Earnings Per Share (Basic) | (1.61) | (27.13) | (1.28) | (1.31) | (162.30) | (278.14) | (11.42) | (61.85) |
| Earnings Per Share (Diluted) | (1.61) | (27.13) | (1.28) | (1.31) | (162.30) | (278.14) | (11.42) | (61.85) |
| Weighted Average Shares Outstanding (Basic) | 1,241 | 98.00 | 2,621 | 2,205 | 19.00 | 7.00 | 186.00 | 36.00 |
| Weighted Average Shares Outstanding (Diluted) | 1,241 | 98.00 | 2,621 | 2,205 | 19.00 | 7.00 | 186.00 | 36.00 |
Scroll the table sideways for older periods — the line-item column and the period header stay put. Hover a row and use the chart handle to plot it over the full history.
About GRI
GRI Bio, Inc. (NASDAQ: GRI) is a stock listed on the Nasdaq Stock Market under the ticker symbol GRI. It last traded at $1.70 (Nov 13, 2026, 4:00 PM ET), down 6.6% on the day. That gives GRI Bio a market capitalisation of $3.7M.
Over the past 52 weeks GRI has traded between $1.36 and $64.12.
For the quarter ended Mar 31, 2026 it reported a net loss of $2.0M.
| Quarter ended | Revenue | Net income |
|---|---|---|
| Mar 31, 2026 | — | -$2.0M |
| Dec 31, 2025 | — | -$2.7M |
| Sep 30, 2025 | — | -$3.4M |
| Jun 30, 2025 | — | -$2.9M |
From GRI Bio’s quarterly (10-Q) filings, in US dollars.
Take a break — play a market game
Seven free games built around the markets. No download, no sign-up: they run right here in your browser.
Latest News
Market news from around the web — every story is an open thread, so give it a like or add your take.
Loading news…